Clinical trials: Resectable Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to evaluate the safety of treatment with Eye90 microspheres in patients with unresectable Hepatocellular Carcinoma (HCC) and metastatic Colorectal Cancer (mCRC).
- Conditions
- Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer, Liver Cancer
- Trial name
- NCT04926376
- Testing
- Eye90 Microspheres
- Where
- New Zealand
- Volunteers
- 8 people
- Sponsor
- ABK Biomedical
Hepatocellular Carcinoma
Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC
This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to explore the efficacy and safety of Sorafenib combined with transarterial chemoembolization as adjuvant treatment for resectable advanced…
- Trial name
- SOURCE (NCT04143191)
- Testing
- Sorafenib, Transarterial chemoembolization
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable
HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients
Patients with hepatocellular carcinoma often die from intrahepatic disease since current treatment options are generally limited.
- Trial name
- NCT03379844
- Testing
- Holmium-166 radioembolization
- Where
- 2 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- UMC Utrecht
Hepatocellular Carcinoma Non-resectable
Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma
The study investigates the adjuvant SBRT following TACE in early and intermediate stages HCC not amenable for surgical resection.
- Trial name
- ASTrH (NCT04996914)
- Testing
- TACE, SBRT
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- RWTH Aachen University
Resectable Hepatocellular Carcinoma
Neoadjuvant Triple Therapy for Resectable HCC
This study is a single-arm, multi-center, prospective phase II trial aimed at evaluating the efficacy and safety of neoadjuvant therapy with transarterial chemoembolization (TACE) combined with lenvatinib and camrelizumab (triple…
- Trial name
- TALENP001 (NCT06569498)
- Where
- 6 sites in China
- Volunteers
- 20 people
- Sponsor
- Fujian Provincial Hospital
Hepatocellular Carcinoma
Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Patients with hepatocellular carcinoma with PVTT can benefit from surgical resection and radiotherapy. As the rapid development of systematic treatment in hepatocellular carcinoma, ICIs neoadjuvant therapy is being actively…
- Trial name
- NCT05225116
- Testing
- Sintilimab, Lenvatinib, radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Hepatocellular Carcinoma
Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC
This is a Phase Ib study to evaluate the safety and efficacy of sintilimab combined with bevacizumab biosimilar in patients with potentially resectable intermediate hepatocellular carcinoma (HCC).
- Trial name
- NCT04843943
- Testing
- Sintilimab, Bevacizumab Biosimilar
- Volunteers
- 30 people
- Sponsor
- Fudan University
HCC - Hepatocellular Carcinoma
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
This is a prospective, multicenter, randomized controlled, phase 3 study to explore the efficacy and safety of neoadjuvant tislelizumab plus lenvatinib in patients with resectable HCC at high risk of recurrence.
- Trial name
- Neo-LENTIS (NCT07475026)
- Testing
- Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
This phase II trial studies the side effects and how well nivolumab with or with ipilimumab works in treating patients with liver cancer that can be removed by surgery.
- Trial name
- NCT03222076
- Testing
- Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Hepatic Carcinoma Malignant Primary Non-Resectable
Liquid Biopsy in Hepatocellular Carcinoma
Circulating tumor DNA (ctDNA) carrying tumor-specific sequence alterations has been found in the cell-free fraction of blood. Hepatocellular carcinoma (HCC) specimens are difficult to obtain, and noninvasive methods are required…
- Trial name
- HCCGenePanel (NCT04111029)
- Testing
- Cell Free DNA
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Liver, Cancer of, Non-Resectable
QuiremSpheres Observational Study
The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT…
- Trial name
- Hope166 (NCT03563274)
- Testing
- Selective Internal Radiation Therapy with QuiremSpheres®
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 20 people
- Sponsor
- Terumo Europe N.V.
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma
This is a prospective, single-blinded, single-arm, open-label Phase II trial of trans-arterial radiation segmentectomy using Yttrium-90 glass microspheres (TheraSphere®) for Hepatocellular Carcinoma (HCC) participants with…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable
- Trial name
- NCT07110233
- Testing
- TheraSphere® Yttrium-90 microspheres, Health Related Quality of Life Questionnaires (HRQOL)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, San Francisco
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
HCC - Hepatocellular Carcinoma
A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
This study aims to explore the value of the 'HAIC Apatinib Camrelizumab' triple regimen for perioperative treatment of resectable hepatocellular carcinoma.
- Trial name
- NCT07618546
- Testing
- Camrelizumab (anti-PD-1 inhibitor), Apatinib Mesylate Tablets, FOLFOX-HAIC
- Volunteers
- 208 people
- Sponsor
- Henan Cancer Hospital
Resectable Hepatocellular Carcinoma
Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
This is a prospective, one-arm, phase II clinical study of Tislelizumab combined with Lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.
- Trial name
- NCT04834986
- Testing
- Tislelizumab combined with Lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma (HCC)
Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
Dear Sir/Madam, We would like to invite you to participate in this clinical research, which has been approved by the Medical Ethics Committee of Zhejiang Cancer Hospital.
- Trial name
- HAICI (NCT06741020)
- Testing
- Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma Non-resectable, Conversion
Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy
To compare the prognosis and adverse reactions of unresectable hepatocellular carcinoma receiving stereotactic radiotherapy combined with hepatic arterial chemoembolization and conversion hepatectomy
- Trial name
- NCT05057104
- Volunteers
- 320 people
- Sponsor
- Beijing 302 Hospital
Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
This phase II trial studies the effect of atezolizumab and bevacizumab before surgery in treating patients with liver cancer that can be removed by surgery (resectable).
- Conditions
- Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8, Stage IB Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT04721132
- Testing
- Atezolizumab, Bevacizumab, Therapeutic Conventional Surgery
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
RATIONALE: Learning about the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients live more comfortably.
- Trial name
- NCT00274885
- Testing
- oxaliplatin, management of therapy complications
- Where
- 6 sites in France
- Volunteers
- 58 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group